Oncolytic Virus-Based Gene Therapy Market Size, Report by 2034

Oncolytic Virus-Based Gene Therapy Market Overview

The global market for oncolytic virus-based gene therapy is expanding as engineered viruses create new avenues for targeting and destroying tumor cells while also enhancing immune responses. This growth is fueled by the increasing prevalence of cancer, demand for innovative treatments, and advancements in genetic engineering and viral vector technology. North America accounted for approximately 45% of the market share in 2024, while the Asia Pacific region is projected to experience the highest growth rate, at an estimated CAGR of 15% from 2025 to 2034.

Key findings include that the herpes simplex virus (HSV) segment held a market share of 30%, while the reovirus segment is expected to grow at a CAGR of about 30%. The intravenous delivery method captured approximately 40% of the market, and the melanoma segment led cancer types with a market share of 25%. Pharmaceutical and biotechnology companies represented about 50% of market end-users.

Why it Matters

• Understanding emerging therapies can inform investment decisions and health policies in oncology.
• Awareness of market dynamics may enhance the development of targeted therapies for specific cancer types.

The Latest

• UroGen Pharma Ltd. announced the acquisition of the next-generation oncolytic virus ICVB-1042 in February 2025, emphasizing its commitment to innovative therapies for bladder cancer.